Fact CheckerSign in

NCT06286956Active, not recruiting

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device

Source: ClinicalTrials.gov · Last updated 27 Mar 2025

Brief summary (registry, in English)

The aim of the clinical trial is to investigate whether the use of a new multichannel endoscopic transanal access device (named UNI-VEC) is safe and effective in the resection of a rectal polyp or tumor that sits in the distal part of the colon (up to about 20 cm from the anal margin). This is the first study to test the device in humans, after proving its good performance in preclinical development (preclinical development has included functional laboratory tests and an animal trial).

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
40 (actual)
First submitted
12 Feb 2024
Start date
19 Apr 2021
Primary completion date
3 Jan 2025
Lead sponsor
Vecmedical Spain, S.L.
NCT number
NCT06286956

What you commit to

  • Study type: Interventional
  • Participants enrolled: 40
  • From 19 Apr 2021 to the primary completion date, 3 Jan 2025
  • 11 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • They suffer from hematological diseases with altered coagulation of their own or pharmacologically induced coagulation disorders (the use of acetylsalicylic acid (ASA) in doses of 150 mg/day is permitted).

Other

  • Are considered vulnerable subjects.
  • Have rectal lesions that lie above the pectineal line or extend into the anal canal.
  • Local or distant metastasis.
  • Have a score of more than 2 points on the Wexner faecal incontinence scale.

Who the study is looking for

  • All polyps included in the Paris Classification (Polypoid (0-I): Sessile type (Is), Pedunculated type (Ip), Non-polypoid (0-II, III): Raised type (IIa), Flat type (IIb), Depressed type (IIc), Excavated type (III))
  • Lesions located from the anal margin to about 20 cm.
  • Extent of at least 2 cm² (polyps 2 cm in diameter or areas of ERM or ESD 2 x 2 cm).
  • Well or moderately differentiated tumours. T1: Tumours confined to the mucosa (Tis) and submucosa (T1).
  • No positive lymph nodes.
  • No lymphatic, vascular or perineural invasion.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (11)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Complexo Hospitalario Universitario de A Coruña
Coordinator of this site? Confirm its status
A CoruñaSpainUnknown status
Hospital Quirón-Salud A Coruña
Coordinator of this site? Confirm its status
A CoruñaSpainUnknown status
Hospital del Mar
Coordinator of this site? Confirm its status
BarcelonaSpainUnknown status
Hospital Universitario de Cabueñes
Coordinator of this site? Confirm its status
GijónSpainUnknown status
Hospital Universitario Lucus Augusti
Coordinator of this site? Confirm its status
LugoSpainUnknown status
Hospital La Paz
Coordinator of this site? Confirm its status
MadridSpainUnknown status
Hospital Universitario Reina Sofía de Murcia
Coordinator of this site? Confirm its status
MurciaSpainUnknown status
Hospital Universitari Mútua de Terrassa
Coordinator of this site? Confirm its status
TerrassaSpainUnknown status
Hospital Universitario la Fe
Coordinator of this site? Confirm its status
ValenciaSpainUnknown status
Hospital Universitario Rio Hortega
Coordinator of this site? Confirm its status
ValladolidSpainUnknown status
Complejo Hospitalario Universitario de Vigo
Coordinator of this site? Confirm its status
VigoSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.